Skip to main content

Table 1 Demographic data and clinical disposition at baseline (ITT, N = 626)

From: Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial

Variable

CH group

CR group

(N = 313)

(N = 313)

Gender, n (%)

Male

167 (53.4)

170 (54.3)

Female

146 (46.6)

143 (45.7)

Age [years], mean (SD)

50.8 (14.6)

48.8 (14.0)

Weight [kg], mean (SD)

81.8 (16.4)

83.4 (17.4)

BMI [kg/m2], mean (SD)

28.0 (5.1)

28.6 (5.7)

Race, n (%)

Asian

14 (4.5)

7 (2.2)

Black

13 (4.2)

17 (5.4)

White

246 (78.6)

253 (80.8)

Other

40 (12.8)

36 (11.5)

GI comorbidities, n (%)

Dyspepsia-like

204 (65.2)

201 (64.2)

IBS-like

44 (14.1)

41 (13.1)

Current smoker, n (%)

 

79 (25.2)

83 (26.5)

ReQuestTM total score

 

10.23

11.37

GERDyzerTM sum score

 

46.12

49.45

  1. CH classical healing, CR complete remission, IBS irritable bowel syndrome, ITT intention-to-treat, N number of patients, BMI body mass index, SD standard deviation.